scholarly article | Q13442814 |
P50 | author | Aaron Ciechanover | Q233205 |
Gordon B. Mills | Q28086262 | ||
Matias A Bustos | Q94459359 | ||
P2093 | author name string | Ying Mao | |
Xiaowen Wang | |||
Kevin Tran | |||
Dave S B Hoon | |||
Daniel F Kelly | |||
Romela Irene Ramos | |||
Xiaoqing Zhang | |||
Cong Tan | |||
Matthew P Salomon | |||
Shu-Ching Chang | |||
Yuuki Iida | |||
Yelena Kravtsova-Ivantsiv | |||
Rebecca Gentry | |||
P2860 | cites work | Multivariate or multivariable regression? | Q24601735 |
IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing | Q26801060 | ||
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age | Q26830388 | ||
USP19 deubiquitinating enzyme supports cell proliferation by stabilizing KPC1, a ubiquitin ligase for p27Kip1 | Q28583199 | ||
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy | Q33762745 | ||
A pan-cancer proteomic perspective on The Cancer Genome Atlas. | Q33944976 | ||
Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase | Q34365993 | ||
Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. | Q35711136 | ||
Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. | Q36557197 | ||
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy | Q36591350 | ||
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue | Q36695468 | ||
Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness | Q36982983 | ||
The ubiquitin-proteasome system and activation of NF-κB: involvement of the ubiquitin ligase KPC1 in p105 processing and tumor suppression | Q36998038 | ||
The diverse and complex roles of NF-κB subunits in cancer | Q37976939 | ||
NF-κB and the link between inflammation and cancer | Q37995696 | ||
The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. | Q38093473 | ||
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. | Q38480250 | ||
Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy | Q38624686 | ||
NFKB1: a suppressor of inflammation, ageing and cancer | Q38668336 | ||
Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. | Q38847201 | ||
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro. | Q38925936 | ||
KPC1-mediated ubiquitination and proteasomal processing of NF-κB1 p105 to p50 restricts tumor growth | Q42475469 | ||
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer | Q43807549 | ||
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. | Q45918451 | ||
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. | Q46410671 | ||
Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination | Q47126029 | ||
E3 ubiquitin ligases in cancer and implications for therapies | Q47636038 | ||
The roles of ubiquitin modifying enzymes in neoplastic disease | Q47783548 | ||
High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas | Q48452453 | ||
WHO 2016 Classification of gliomas. | Q50501884 | ||
Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. | Q53509559 | ||
Predominance of triple wild-type and IGF2R mutations in mucosal melanomas | Q58093307 | ||
Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes | Q58556913 | ||
Significance of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1 (PAI-1) Expression in Human Colorectal Carcinomas | Q62606080 | ||
The landscape of the mesenchymal signature in brain tumours | Q64101370 | ||
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients | Q77493218 | ||
KPC1 expression and essential role after acute spinal cord injury in adult rat | Q83180931 | ||
The unravelling of the ubiquitin system | Q87176733 | ||
[A plasminogen regulation system in brain tumors] | Q88106467 | ||
Comparison of glioblastoma (GBM) molecular classification methods | Q90384559 | ||
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets | Q90734706 | ||
Stabilization of p27Kip1/CDKN1B by UBCH7/UBE2L3 catalyzed ubiquitinylation: a new paradigm in cell-cycle control | Q90977486 | ||
Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease | Q99351983 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 5 | |
P921 | main subject | glioblastoma | Q282142 |
P577 | publication date | 2020-04-27 | |
P1433 | published in | Cancers | Q27722963 |
P1476 | title | Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors | |
P478 | volume | 12 |
Search more.